scholarly journals Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient

2018 ◽  
Vol 48 (10) ◽  
pp. 1764-1767 ◽  
Author(s):  
Yuko Horio ◽  
Koutaro Takamatsu ◽  
Daisuke Tamanoi ◽  
Ryo Sato ◽  
Koichi Saruwatari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Lung Cancer Patient ◽  
Immune Checkpoint Blockade ◽  
Small Cell ◽  
Checkpoint Blockade ◽  
Small Cell Lung

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9052-9052 ◽  
Author(s):  
Marcelo Vailati Negrao ◽  
Alexandre Reuben ◽  
Jacqulyne Ponville Robichaux ◽  
Xiuning Le ◽  
Monique B. Nilsson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Small Cell ◽  
Checkpoint Blockade ◽  
Small Cell Lung ◽  
Her 2 ◽  
Exon 20

Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 8556-8556 ◽  
Author(s):  
Wei-Chu Victoria Lai ◽  
Hira Rizvi ◽  
Jacklynn V. Egger ◽  
Andrew J. Plodkowski ◽  
Michelle S. Ginsberg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Immune Checkpoint ◽  
Objective Response ◽  
Immune Checkpoint Blockade ◽  
Small Cell ◽  
Checkpoint Blockade ◽  
Small Cell Lung

8556 Background: Immune checkpoint blockade (ICB) is now a routine component of treatment in recurrent small cell lung cancer (SCLC). We evaluated the response to ICB in patients (pts) with recurrent SCLC and genomic features of response using next-generation sequencing (NGS). Methods: Pts with recurrent SCLC treated with ICB were identified. The majority of pts were treated outside of a clinical trial to focus emphasis on the real-world experience. Tumor mutation burden (TMB) and the landscape of somatic variants were determined by targeted NGS using MSK-IMPACT. Objective response rate (ORR) to ICB was determined using RECIST v1.1. PFS and OS were measured from the start of ICB and analyzed using Kaplan-Meier. Results: Between December 2013 and October 2018, 108 pts with SCLC were treated with ICB (57 subjected to NGS). Pts received PD-1 monotherapy alone (n = 28) or in combination with CTLA-4 blockade (n = 80). Median line of therapy was 2 (range 1-6). ORR was 14% (15/108, 95% CI 8-22%). From the start of ICB, median PFS was 1.4 months in non-responders and 10.8 months in responders (HR 0.2; 95% CI 0.13-0.32). Median OS was 6.3 months in non-responders and undefined in responders (range 8-44 months) (HR 0.26, 95% CI 0.16-0.44). Four responders remain on ICB treatment. TMB in the ICB-treated cohort was similar to that of an unselected cohort (n = 233) of SCLC (median 8.8 Mt/MB vs 8.2 Mt/MB, p = 0.71). Clinical benefit was enriched among those with a higher TMB (upper vs middle/lower tertile PFS HR 0.48, 95% CI 0.28-0.84, p = 0.01 and ORR 26% [5/19] vs ORR 8% [3/38]). Rates of whole genome duplication and commonly altered genes in SCLC ( TP53, RB1, KMT2C/D, NOTCH1/2/4, PTPRD, APC) were similarly distributed across responders and non-responders. Completion of whole-exome sequencing and PD-L1 testing is in progress. Conclusions: In pts with recurrent SCLC receiving routine clinical care, the ORR to ICB is comparable to reports from clinical trials. A high TMB was associated with a longer median PFS and better response. Further investigation into the genomic landscape of recurrent SCLC is needed to identify biomarkers predictive of response to ICB.

scholarly journals Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

ESMO Open ◽  
2016 ◽  
Vol 1 (4) ◽  
pp. e000022 ◽  
Author(s):  
Luca Paglialunga ◽  
Zena Salih ◽  
Biagio Ricciuti ◽  
Raffaele Califano
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Small Cell ◽  
Checkpoint Blockade ◽  
Small Cell Lung

Immune checkpoint blockade in small cell lung cancer

Lung Cancer ◽  
2019 ◽  
Vol 137 ◽  
pp. 31-37 ◽  
Author(s):  
Rebecca Y. Tay ◽  
David Heigener ◽  
Martin Reck ◽  
Raffaele Califano
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Small Cell ◽  
Checkpoint Blockade ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document